Preclinical Safety Evaluation and Human Dosimetry of [18F]MK-6240, a Novel PET Tracer for Imaging Neurofibrillary Tangles.

Purpose: [18F]MK-6240 is a selective, high-affinity positron emission tomography tracer for imaging neurofibrillary tangles, a key pathological signature that correlates with cognitive decline in Alzheimer disease. This report provides safety information from preclinical toxicology studies and first...

Descripción completa

Detalles Bibliográficos
Publicado en:Molecular Imaging & Biology Vol. 22; no. 1; pp. 173 - 181
Autores principales: Koole, Michel, Lohith, Talakad G., Valentine, John L., Bennacef, Idriss, Declercq, Ruben, Reynders, Tom, Riffel, Kerry, Celen, Sofie, Serdons, Kim, Bormans, Guy, Ferry-Martin, Sandrine, Laroque, Philippe, Walji, Abbas, Hostetler, Eric D., Briscoe, Richard J., de Hoon, Jan, Sur, Cyrille, Van Laere, Koen, Struyk, Arie
Formato: research Journal Article
Publicado: Springer Nature Feb2020
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=141727737&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 141727737
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        15361632
        KJU
      jtl: Molecular Imaging & Biology
      issn: 15361632
      maglogo: N
    pubinfo:
      dt: Feb2020
      vid: 22
      iid: 1
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        141727737
        141727737
        NLM31111397
        141727737
        10.1007/s11307-019-01367-w
        NLM31111397
        141727737
      ppf: 173
      ppct: 8
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: Preclinical Safety Evaluation and Human Dosimetry of [18F]MK-6240, a Novel PET Tracer for Imaging Neurofibrillary Tangles.
      aug:
        au:
          Koole, Michel
          Lohith, Talakad G.
          Valentine, John L.
          Bennacef, Idriss
          Declercq, Ruben
          Reynders, Tom
          Riffel, Kerry
          Celen, Sofie
          Serdons, Kim
          Bormans, Guy
          Ferry-Martin, Sandrine
          Laroque, Philippe
          Walji, Abbas
          Hostetler, Eric D.
          Briscoe, Richard J.
          de Hoon, Jan
          Sur, Cyrille
          Van Laere, Koen
          Struyk, Arie
        affil: Division of Nuclear Medicine, Leuven University Hospitals and UZ Leuven, Leuven, Belgium
      sug:
        subj:
          Neurons Pathology
          Radiometry Methods
          Isoquinolines Pharmacokinetics
          Fluorine Radioisotopes Pharmacokinetics
          Alzheimer's Disease Pathology
          Diagnostic Imaging Methods
          Female
          Male
          Human
          Alzheimer's Disease Metabolism
          Rats
          Alzheimer's Disease
          Radiopharmaceuticals Pharmacokinetics
          Patient Safety
          Neurons Metabolism
          Animal Studies
          Research Subjects
          Validation Studies
          Comparative Studies
          Evaluation Research
          Multicenter Studies
          Female
          Male
      ab: Purpose: [18F]MK-6240 is a selective, high-affinity positron emission tomography tracer for imaging neurofibrillary tangles, a key pathological signature that correlates with cognitive decline in Alzheimer disease. This report provides safety information from preclinical toxicology studies and first-in-human whole-body biodistribution and dosimetry studies of [18F]MK-6240 for its potential application in human brain imaging studies.Procedures: MK-6240 was administered intravenously (IV) in a 7-day rat toxicity study at × 50, × 100, and × 1000 dose margins relative to projected highest clinical dose of 0.333 μg/kg. The IV formulation of MK-6240 for clinical use and the formulation used in the 7-day rat toxicity study was tested for hemolysis potential in human and Wistar rat whole blood. Sequential whole-body positron emission tomography scans were performed in three healthy young subjects after IV bolus injection of 180 ± 0.3 MBq [18F]MK-6240 to characterize organ biodistribution and estimate whole-body radiation exposure (effective dose).Results: MK-6240 administered IV in a 7-day rat toxicity study did not show any test article-related changes. The no-observed-adverse-effect level in rats was ≥ 333 μg/kg/day which provides a margin 1000-fold over an anticipated maximum clinical dose of 0.333 μg/kg. Additionally, the MK-6240 formulation was not hemolytic in human or Wistar rat blood. [18F]MK-6240 activity was widely distributed to the brain and the rest of the body, with organ absorbed doses largest for the gall bladder (202 μGy/MBq). The average (±SD) effective dose was 29.4 ± 0.6 μSv/MBq, which is in the typical range for F-18 radiolabeled ligands.Conclusions: Microdoses of [18F]MK-6240 are safe for clinical positron emission tomography imaging studies. Single IV administration of 185 MBq (5 mCi) [18F]MK-6240 is anticipated to result in a total human effective dose of 5.4 mSv and thus allows multiple positron emission tomography scans of the same subject per year.
      pubtype: Academic Journal
      doctype:
        research
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N